Background: Postmenopausal hormone replacement therapy (HRT) relieves menopausal symptoms and may decrease mortality in recently postmenopausal women, but increases breast cancer risk. Low-dose tamoxifen has shown retained activity in phase-II studies.
Given the increase in life expectancy, the management of postmenopausal disorders is a public health issue. Two Women's Health Initiative (WHI) trials testing hormone replacement therapy (HRT) in women with a mean age over 60 years showed a worsened global health index with HRT [1, 2] . The lack of benefit in coronary disease, in contrast to prior observational studies [3] , and the increased risk of breast cancer in the combined conjugated equine estrogen (CEE) plus progestin therapy with the medroxyprogesterone acetate (MPA) trial [1] , led to a dramatic drop in HRT use also in recently postmenopausal women [4, 5] , with a consequent decrease of breast cancer [6] .
The timing of initiation of HRT after the menopause (gap-time) has been advocated as an important reason for the divergent findings on cardiovascular disease between observational studies and the WHI trials [7, 8] , and subsequent analyses of both WHI trials indicated that total and cardiovascular mortality were reduced in women aged 50-59, particularly with CEE alone, in contrast to an increase in women who started HRT >20 years since menopause [9] . However, such a gap-time effect could not be detected on breast cancer in WHI trials as most participants started HRT after 10 years since menopause [9] , whereas observational studies examining HRT use for menopausal symptoms showed a higher breast cancer risk in women starting HRT within 5 years from menopause, including unopposed estrogen therapy [10] [11] [12] . Since HRT use in recently postmenopausal women alleviates menopausal symptoms and decreases bone fracture risk [8] and, possibly, overall mortality in estrogen-alone users [9, 13] , a reduction of breast cancer risk would further ameliorate HRT cost-benefit ratio.
Subgroup analyses of breast cancer prevention trials showed fewer breast cancers in current or past HRT users allocated to either tamoxifen [14, 15] or raloxifene [16] versus placebo. The increased risk of breast cancer associated with HRT is linked to higher expression of estrogen receptors in normal breast tissue [17] , thus leading to enhanced antiestrogen sensitivity. Conversely, the use of a progestin may attenuate the endometrial effects of tamoxifen [18] . Recent dose-ranging trials defined 5 mg/day of tamoxifen as the optimal biological dose based upon a retained activity on surrogate biomarkers [19] [20] [21] and the lack of endometrial proliferation in HRT users [22] . We therefore conducted a phase-III prevention trial to determine the efficacy of low-dose tamoxifen in reducing breast cancer risk in recently postmenopausal women on HRT.
methods subjects and treatment
We conducted a phase-III, double-blind, placebo-controlled trial in recently postmenopausal women using HRT for menopausal symptom relief who were randomly allocated to either placebo or tamoxifen 5 mg/day for 5 years (trial IEO S51/200, HRT opposed by low-dose tamoxifen, HOT, Clinical Trials.gov NCT01579734). Eligibility criteria were current HRT use or de novo HRT use and negative mammography within 6 months. Toxicity was evaluated using the NCI toxicity criteria v2.0. Clinical examinations were repeated every 6 months and mammography was repeated annually. Transvaginal ultrasounds were carried out at baseline and repeated in case of atypical bleeding, followed by hysteroscopy on clinical judgment. At completion of the 5-year intervention, clinical visit and mammography were repeated annually up to 10 years. The use of venflaxine was allowed. The primary end point was the incidence of breast cancer, whereas the secondary end points included endometrial cancer, coronary heart syndrome, cerebrovascular events, venous thromboembolic events (VTEs), bone fractures, all cancers.
pathology and immunohistochemistry
Central pathology assessment of breast cancer included histological type, grade, peritumoral vascular invasion, ER, PgR, HER2 and Ki-67, as previously described [23] . Molecular tumor subtypes were classified by immunohistochemistry (IHC) into four categories according to 2011 St Gallen criteria [24] : luminal-A, ER or PgR-positive and Ki-67 < 14%; luminal-B, ER or PgR-positive and either Ki-67 ≥ 14% with negative HER2 or HER2-positive regardless of the Ki-67 level; HER2-positive and ER/PgRnegative; triple negative, all receptors negative.
sample size and statistical analysis
The study was designed to detect a 40% reduction of breast cancer with 80% power and two-sided 5% significance level. Using the log-rank test, 126 breast cancers had to be observed on 8500 subjects recruited over 5 years with 80% compliance and a background incidence rate of 4/1000. Recalculations based on a hazard ratio (HR) of 0.5, closer to the range observed in the Italian tamoxifen trial [14] , and practical considerations based on the dramatic drop of HRT use after the first WHI trial results [1] led to a total of 4500 women to be recruited to attain the pre-specified assumptions. The decision to stop recruitment was recommended by the Data Safety and Monitoring Committee (DSMC) after a limited recruitment in the last 24 months.
Stratification factors were center, HRT use (current, de novo), route of estrogen administration (transdermal, oral) and prior hysterectomy (unopposed estrogen, combined estrogen-progestin therapy). An ad hoc computer program in Access was used to preserve the allocation ratio in each stratum through biased coin randomization and minimization.
The data included are based on information received as of 30 November 2011 . The main analysis was carried out on an intention-to-treat (ITT) basis. Incidence rates for breast cancer were calculated by dividing the number of events by the number of event-specific person-years of follow-up. For symptoms and adverse events, person-years were calculated from the date of randomization to treatment termination, development of the specific event or dropout, whichever came first.
For other cancers and deaths, person-years were calculated from the date of randomization to the date of last follow-up or specific event. Event rates were compared by using risk ratios (RRs) and 95% confidence intervals (CIs), assuming that the events followed a Poisson distribution. Because healthy, middle-aged women were enrolled in the trial, mortality was not a major competing risk of failure. The two treatment groups were compared by the log-rank test. HRs and 95% CIs were obtained using a Cox proportional regression model after adjustment for age (in 5-year groups) and center. We tested the proportional hazards assumption by introducing a time-dependent variable and testing for its statistical significance. For breast cancer subtypes, follow-up was censored at diagnosis of any other breast cancer subtype. We carried out sensitivity analyses adjusted for nonadherence by censoring follow-up 6 months after women became nonadherent, i.e. took treatment for less than 80% of the planned intervention, or to women who completed at least 12 months of treatment. P-values were at <0.05 level for the main end points and at <0.01 level for secondary end points and subgroup analyses to account for multiple comparisons. Analyses were carried out with SAS software (version 8.2, Cary, NC). Figure S1 , available at Annals of Oncology online. Compliance at the end of 5 years was 55.6% on placebo and 52.6% on tamoxifen (P = 0.19). At the end of follow-up, 1025 (54%) women were still on HRT; 88 (5%) had temporarily suspended HRT or were on HRT every other day and 584 (31%) had definitely stopped HRT. Information was missing for 187 (10%) women. A similar number of women stopped HRT in either arm (n = 289 on placebo and n = 295 on tamoxifen, P = 0.46).
The main subject characteristics were evenly distributed by allocated arm (Table 1 ). The mean ± SD age was 53.1 ± 5.1 on placebo and 53.5 ± 5.0 on tamoxifen, and mean + SD BMI 24.0 ± 3.8. Approximately 20% were de novo HRT users, over 55% were on HRT for <5 years, <20% started HRT >5 years since menopause and only 4% started HRT >10 years since menopause (overall mean ± SD, 3.0 ± 3.5 years). Estrogen therapy at baseline included 92% on estradiol, of whom 10% at low dose (1 mg), CEE users were 8%, of whom 3% at low dose (0.3 mg). Table S1 , available at Annals of Oncology online). The cumulative incidence of breast cancer, overall and by molecular subtypes is illustrated in Figure 1 .
In sensitivity analyses shown in Figure 2 , censoring follow-up 6 months after women became nonadherent (i.e. took treatment for <4 years), tamoxifen showed a greater risk reduction of breast cancer, with 24 events on placebo versus 13 on tamoxifen (age adjusted HR 0.59; 95% CI 0.30-1.17). Similarly, in women who completed at least 12 months of treatment, the number of events was 23 versus 14 (HR, 0.65; 95% CI 0.33-1.26). In an efficacy analysis restricted to women who completed at least 12 months of treatment and censoring follow-up 6 months after women became nonadherent, the number of events was 23 versus 10 (HR, 0.49; 95% CI 0.23-1.02). Table 3 summarizes protocol pre-specified menopausal symptoms and adverse events by allocated arm. Moderate or severe (grade 2 or higher) hot flashes, night sweats, vaginal dryness and discharge were significantly more frequent on tamoxifen than on placebo, whereas headache was significantly less frequent on tamoxifen. Pre-specified serious adverse events were not different between placebo and tamoxifen, including coronary heart syndrome (6 versus 4), cerebrovascular events (2 versus 5, including four TIA on tamoxifen) and VTE (2 versus 5, including one superficial VTE on tamoxifen), respectively. There were six cases of endometrial polyps on placebo and 27 on tamoxifen, leading to drug withdrawal in 2 versus 10 cases, respectively (P = 0.016). There was no increase of uterine cancer on tamoxifen (3 on placebo versus 1 on tamoxifen). No clinical bone fractures were recorded. The cumulative incidence of pre-specified adverse events is illustrated in supplementary Figure S2 , available at Annals of Oncology online. The rate of grade 2-3 menopausal symptoms was 50%-80% higher on tamoxifen versus placebo. There were 15 cancers other than breast on placebo and 14 on tamoxifen, and 2 versus 6 deaths (supplementary Table S2 , available at Annals of Oncology online).
discussion
A basic principle of clinical endocrinology indicates that hormone deficiency should be replaced when it is clinically relevant [8] . Although life expectancy has dramatically increased over the last century, age at menopause has shown only a small increase [25] . The aim of this pragmatic trial was to assess the efficacy of 5 mg/day of tamoxifen in reducing breast cancer in recently postmenopausal women treated with different HRT forms for menopausal symptom relief. We found a nonsignificant 20% reduction of breast cancer with low-dose tamoxifen, a figure similar to that obtained with 20 mg/day in hysterectomized women [14] . Unfortunately, the negative impact of the WHI findings on HRT prescriptions in recently [4, 5, 8] despite the different indications and age range heavily hampered our recruitment capability. Subgroup analyses showed that tamoxifen exhibited a favorable trend on luminal-A tumors and tumors expressing PgR, which are known to be associated with HRT use [26] and to be highly endocrine responsive [24] . Tamoxifen also showed a lower breast cancer risk in women on HRT <5 years, who had the highest risk among HRT users, consistent with the gap-time effect [10] [11] [12] , and among ERT-alone users, where the longterm risk of breast cancer incidence and death is decreased, at least with CEE [27] . In contrast, tamoxifen had no effect in the combined HRT subgroup, where the risk of breast cancer incidence and mortality is increased [28, 29] .Sensitivity analysis adjusted for nonadherence and restricted to women who took treatment for more than 1 year yielded a 50%, borderline significant reduction of breast cancer by low-dose tamoxifen. All these subgroup analyses have limited power, however, and none were significant at P < 0.01, so the results should be interpreted with caution.
We found no excess of cardiovascular events and VTE on tamoxifen, in line with the observation that the risk of VTE under tamoxifen is attenuated by concomitant ERT use [30] and in premenopausal women [31] . Also, the rates of serious adverse events seem to be lower with 5 mg/day than with 20 mg/day in a similar population [14] , possibly because tamoxifen estrogenicity is attenuated by a lower dose [20] . Although significantly more endometrial polyps were noted on tamoxifen, no increase of endometrial cancer was observed, again suggesting a protective effect of progestins against tamoxifen endometrial effects [18, 32] . However, a clear relationship between endometrial polyps and subsequent endometrial cancer under tamoxifen has not been established [33] .
Despite the concomitant use of HRT, low-dose tamoxifen increased the rate of grade 2-3 hot flashes by ∼50% (from 64/ 1000 to 97/1000 per year). An indirect comparison suggests that this rate is lower than that observed with tamoxifen at 20 mg/ day in our prior trial in hysterectomized women (from 67/1000 on placebo to 119/1000 on tamoxifen [14] ), but it is still of Risk ratio (RR) for women in the tamoxifen group relative to women in the placebo group. concern given the notion that hot flashes are a major reason for dropout in prevention trials [14, 31] . In both the studies, women were on HRT because of menopausal symptoms or early surgical menopause [14] , and thus represent a selected population with a higher rate of symptoms than the average population treated with tamoxifen. An increase of hot flashes under 20 mg tamoxifen in HRT users has also been reported in the IBIS trial [34] . Because women were not randomly assigned to HRT, however, we cannot determine the magnitude of the effect of HRT on tamoxifen-induced menopausal symptoms.
The 5-year compliance was slightly over 50% in our trial, in line with most breast cancer prevention trials [1, 2, 14, 15, 31] . Yet the high dropout rate remains an important issue that may jeopardize efficacy, as suggested by our sensitivity analyses. Although our study cannot directly apply to different categories such as gene mutation carriers undergoing risk reduction salpingo-oophorectomy, our findings seem to provide safety reassurance on the addition of low-dose tamoxifen to estrogen-alone therapy for menopausal symptom relief in these specific women's populations where there is a clear unmet medical need [35, 36] . A properly designed clinical trial may be warranted.
Our population was mostly composed of recently postmenopausal women undergoing HRT for menopausal symptoms, in contrast to the WHI trials which addressed the preventive effect of HRT in a much older and asymptomatic population. Moreover, only a minority of our participants used oral CEE (8%) and MPA (15%), reflecting the limited prescription of both the drugs in Europe. Admittedly, the lower risk of breast cancer death associated with estrogen therapy alone [27] versus the increased risk in the combined HRT [28, 29] may have contributed to the heterogeneity of our findings. Since subgroup analyses of the WHI trials indicated that estrogen therapy alone has an overall health benefit in women aged <60 years [9, 13] , it is possible that the use of most recent forms of HRT that avoid the systemic effects of MPA will regain consensus in the treatment of recently postmenopausal women [8] . If this is the case, our results are useful as they provide a clue to reduce breast cancer, the major risk associated with HRT use, in a broad population composed of recently postmenopausal women. Although tamoxifen is currently not available as 5 mg tablet in the market, its prolonged half-life allows for alternative schedules with retained activity, such as 10 mg every other day [37, 38] .
Our findings in primary prevention cannot be compared with the HABITS [39] and Stockholm trial [40] , which assessed the effect of HRT in breast cancer survivors, some of whom were being treated with tamoxifen as an adjuvant treatment. The Stockholm trial did not show any difference between HRT arms in tamoxifen users (5 versus 4), whereas in the HABITS trial there was a higher risk of recurrence in the HRT arm among tamoxifen users. However, the proportion of tamoxifen users was lower in HABITS (33% versus 52%). Moreover, because tamoxifen use was not randomized, women may have received the anti-estrogen tamoxifen because of their higher risk of recurrence.
Our study has several important limitations, including the limited statistical power and the marked heterogeneity of HRT types having different risks of breast cancer. For these reasons, reliable conclusions cannot be drawn. However, our trial suggests that the addition of low-dose tamoxifen to HRT may reduce the risk of breast cancer in recently Risk ratio (RR) for women in the tamoxifen group relative to women in the placebo group. CI = confidence interval. Among women who were free of symptoms at baseline.
postmenopausal women. This hypothesis should be assessed in a larger study.
acknowledgements
Tamoxifen and placebo were gifted by FIDIA FarmaceuticiS.p.a, AbanoTerme, Italy. We are grateful to the study participants for their heart and energy. 
